F
Frank Stegmeier
Researcher at Novartis
Publications - 52
Citations - 11228
Frank Stegmeier is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 29, co-authored 46 publications receiving 8855 citations. Previous affiliations of Frank Stegmeier include Howard Hughes Medical Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih Min A Huang,Yuji Mishina,Shanming Liu,Atwood K. Cheung,Frank Stegmeier,Gregory A. Michaud,Olga Charlat,Elizabeth Wiellette,Yue Zhang,Stephanie Wiessner,Marc Hild,Xiaoying Shi,Christine D. Wilson,Craig Mickanin,Vic E. Myer,Aleem Fazal,Ronald Tomlinson,Fabrizio C. Serluca,Wenlin Shao,Hong Cheng,Michael Shultz,Christina Rau,Markus Schirle,Judith Schlegl,Sonja Ghidelli,Stephen Fawell,Chris Lu,Daniel Curtis,Marc W. Kirschner,Christoph Lengauer,Peter Finan,John A. Tallarico,Tewis Bouwmeester,Jeffery A. Porter,Andreas Bauer,Feng Cong +35 more
TL;DR: This study uses a chemical genetic screen to identify a small molecule, XAV939, which selectively inhibits β-catenin-mediated transcription and reveals new mechanistic insights into the regulation of axin protein homeostasis, which presents new avenues for targeted Wnt pathway therapies.
Journal ArticleDOI
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi,Franklin W. Huang,Franklin W. Huang,Franklin W. Huang,Judit Jané-Valbuena,Judit Jané-Valbuena,Gregory V. Kryukov,Christopher Lo,E. Robert McDonald,Jordi Barretina,Ellen Gelfand,Craig M. Bielski,Haoxin Li,Haoxin Li,Kevin Hu,Alexander Y. Andreev-Drakhlin,Jaegil Kim,Julian M. Hess,Brian J. Haas,François Aguet,Barbara A. Weir,Michael V. Rothberg,Brenton R. Paolella,Michael S. Lawrence,Rehan Akbani,Yiling Lu,Hong L. Tiv,Prafulla C. Gokhale,Antoine de Weck,Ali Amin Mansour,Coyin Oh,Juliann Shih,Kevin Hadi,Yanay Rosen,Jonathan Bistline,Kavitha Venkatesan,Anupama Reddy,Dmitriy Sonkin,Dmitriy Sonkin,Manway Liu,Joseph Lehar,Joshua M. Korn,Dale Porter,Michael D. Jones,Javad Golji,Giordano Caponigro,Jordan E. Taylor,Caitlin M. Dunning,Amanda L. Creech,Allison Warren,James M. McFarland,Mahdi Zamanighomi,Audrey Kauffmann,Nicolas Stransky,Marcin Imielinski,Yosef E. Maruvka,Yosef E. Maruvka,Andrew D. Cherniack,Andrew D. Cherniack,Aviad Tsherniak,Francisca Vazquez,Jacob D. Jaffe,Andrew A. Lane,David M. Weinstock,Cory M. Johannessen,Michael Morrissey,Frank Stegmeier,Robert Schlegel,William C. Hahn,William C. Hahn,Gad Getz,Gordon B. Mills,Jesse S. Boehm,Todd R. Golub,Todd R. Golub,Todd R. Golub,Levi A. Garraway,Levi A. Garraway,William R. Sellers,William R. Sellers +79 more
TL;DR: The original Cancer Cell Line Encyclopedia is expanded with deeper characterization of over 1,000 cell lines, including genomic, transcriptomic, and proteomic data, and integration with drug-sensitivity and gene-dependency data, which reveals potential targets for cancer drugs and associated biomarkers.
Journal ArticleDOI
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata,Matthew J. Niederst,Hannah L. Archibald,Maria Gomez-Caraballo,Faria M. Siddiqui,Hillary E. Mulvey,Yosef E. Maruvka,Yosef E. Maruvka,Fei Ji,Hyo-eun C. Bhang,Viveksagar Krishnamurthy Radhakrishna,Giulia Siravegna,Haichuan Hu,Sana Raoof,Elizabeth L. Lockerman,Anuj Kalsy,Dana Lee,Celina L. Keating,David A. Ruddy,Leah J. Damon,Adam S. Crystal,Carlotta Costa,Zofia Piotrowska,Alberto Bardelli,Anthony J. Iafrate,Ruslan I. Sadreyev,Frank Stegmeier,Gad Getz,Lecia V. Sequist,Anthony C. Faber,Jeffrey A. Engelman +30 more
TL;DR: Findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.
Journal ArticleDOI
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells
TL;DR: It is shown that polymerase II-transcribed shRNAs display very efficient knockdown of gene expression when the shRNA is embedded in a microRNA context, which is an important step toward using bar-coding strategies to follow loss of specific sequences in complex populations.
Journal ArticleDOI
PTEN-deficient cancers depend on PIK3CB
Susan Wee,Dmitri Wiederschain,Sauveur Michel Maira,Alice Loo,Christine Miller,Rosalie deBeaumont,Frank Stegmeier,Yung Mae Yao,Christoph Lengauer +8 more
TL;DR: Although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling, demonstrating the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.